Lyfebulb and Bristol Myers Squibb are now accepting applications for the $25,000 Innovation Challenge award, a partnership initiative that aims to raise awareness about multiple sclerosis (MS) and address unmet needs in its management.
The Innovation Challenge, which will take place virtually in March 2021, is open to patient entrepreneurs who have been directly affected by MS as either a patient or support partner for a loved one and whose US-based companies are working to help address challenges that people living with or affected by MS face in their daily lives.
Selected finalists will have the opportunity to pitch their ideas to an expert panel of judges comprised of healthcare industry, medical and patient leaders, and the winner will be awarded a $25,000 monetary grant, Lyfebulb explains in a media release.
Applications for the Innovation Challenge are now being accepted and will be available through December 9, 2020.
“The unpredictable and changing nature of MS symptoms leads to challenges for those living with the disease, and we’re proud to be working with Lyfebulb to bring entrepreneurial members of the community together to identify meaningful, patient-driven solutions.”
— Tina Deignan, Vice President and US Business Unit Head of Immunology at Bristol Myers Squibb
Virtual Speaker Sessions
A series of virtual speaker sessions, leading up to the Innovation Challenge, will take place starting in October 2020 and offer MS community members the opportunity to engage in panel discussions aimed at raising collective awareness of MS and inspiring change. Speaker panels will be comprised of patient and industry leaders as well as 2019 Innovation Challenge alumni.
The speaker sessions will be open to all members of the MS community. For more information about attending, visit Lyfebulb.
“We are thrilled to support this patient-driven innovation in MS in partnership with Bristol Myers Squibb.
“While great strides have been made, the burdens of MS continue to take a toll on the nearly one million people living with the disease in the US, and their support partners. By placing patients at the forefront and spotlighting their voice and solutions, we hope to inspire all members of the community to take charge and create positive change.”
— Dr Karin Hehenberger, CEO and Founder of Lyfebulb
[Source(s): Lyfebulb, PR Newswire]
Related Content:
Multiple Sclerosis Management App Wins MedTech Breakthrough Patient Engagement Innovation Award
This is How Age of Onset May Affect Clinical Outcomes for Multiple Sclerosis Patients
Benign Multiple Sclerosis Predictors Include Younger Age and Earlier Onset
